Literature DB >> 14653307

Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders.

D L Murphy1, G R Uhl, A Holmes, R Ren-Patterson, F S Hall, I Sora, S Detera-Wadleigh, K P Lesch.   

Abstract

Current evidence indicates that virtually all neuropsychiatric disorders, like many other common medical disorders, are genetically complex, with combined influences from multiple interacting genes, as well as from the environment. However, additive or epistatic gene interactions have proved quite difficult to detect and evaluate in human studies. Mouse phenotypes, including behaviors and drug responses, can provide relevant models for human disorders. Studies of gene-gene interactions in mice could thus help efforts to understand the molecular genetic bases of complex human disorders. The serotonin transporter (SERT, 5-HTT, SLC6A4) provides a relevant model for studying such interactions for several reasons: human variants in SERT have been associated with several neuropsychiatric and other medical disorders and quantitative traits; SERT blockers are effective treatments for a number of neuropsychiatric disorders; there is a good initial understanding of the phenotypic features of heterozygous and homozygous SERT knockout mice; and there is an expanding understanding of the interactions between variations in SERT expression and variations in the expression of a number of other genes of interest for neuropsychiatry and neuropharmacology. This paper provides examples of experimentally-obtained interactions between quantitative variations in SERT gene expression and variations in the expression of five other mouse genes: DAT, NET, MAOA, 5-HT(1B) and BDNF. In humans, all six of these genes possess polymorphisms that have been independently investigated as candidates for neuropsychiatric and other disorders in a total of > 500 reports. In the experimental studies in mice reviewed here, gene-gene interactions resulted in either synergistic, antagonistic (including 'rescue' or 'complementation') or more complex, quantitative alterations. These were identified in comparisons of the behavioral, physiological and neurochemical phenotypes of wildtype mice vs. mice with single allele or single gene targeted disruptions and mice with partial or complete disruptions of multiple genes. Several of the descriptive phenotypes could be best understood on the basis of intermediate, quantitative alterations such as brain serotonin differences. We discuss the ways in which these interactions could provide models for studies of gene-gene interactions in complex human neuropsychiatric and other disorders to which SERT may contribute, including developmental disorders, obesity, polysubstance abuse and others.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14653307     DOI: 10.1046/j.1601-1848.2003.00049.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  35 in total

1.  Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior.

Authors:  Georgianna G Gould; Julie G Hensler; Teresa F Burke; Robert H Benno; Emmanuel S Onaivi; Lynette C Daws
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

Review 2.  Refining psychiatric genetics: from 'mouse psychiatry' to understanding complex human disorders.

Authors:  Justin L Laporte; Renee F Ren-Patterson; Dennis L Murphy; Allan V Kalueff
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

Review 3.  Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease.

Authors:  Dennis L Murphy; Pablo R Moya
Journal:  Curr Opin Pharmacol       Date:  2011-03-23       Impact factor: 5.547

4.  Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter.

Authors:  Ana Marin D Carneiro; Randy D Blakely
Journal:  J Biol Chem       Date:  2006-06-27       Impact factor: 5.157

Review 5.  Post-Traumatic Sleep-Wake Disorders.

Authors:  Tatyana Mollayeva; Andrea D'Souza; Shirin Mollayeva; Angela Colantonio
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

6.  Gender-dependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies.

Authors:  Renee F Ren-Patterson; Lauren W Cochran; Andrew Holmes; Klaus-Peter Lesch; Bai Lu; Dennis L Murphy
Journal:  Cell Mol Neurobiol       Date:  2006-09-22       Impact factor: 5.046

7.  Metabolic and reproductive consequences of the serotonin transporter promoter polymorphism (5-HTTLPR) in adult female rhesus monkeys (Macaca mulatta).

Authors:  J B Hoffman; J R Kaplan; B Kinkead; S L Berga; M E Wilson
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

Review 8.  Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter.

Authors:  Alexander Neumeister; Theresa Young; Juergen Stastny
Journal:  Psychopharmacology (Berl)       Date:  2004-07-13       Impact factor: 4.530

Review 9.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

Review 10.  Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity.

Authors:  Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.